NZYM B Novozymes A/S Class B

Total number of voting rights and capital on January 31, 2024

Total number of voting rights and capital on January 31, 2024

        

Total number of voting rights and capital on January 31, 2024







January 31, 2024

Company announcement No. 05
 



Referring to company announcement 02, on January 29, 2024, where Novozymes A/S ("Novozymes") announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292 through the issuance of a total of 187,298,646 new Novozymes B-shares in the denomination of DKK 2 each.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act, it is hereby announced that the total share capital as of today consists of nominally DKK 936,597,292 comprising a total of 468,298,646 shares, divided into 53,743,600 A shares and 414,555,046 B shares with a nominal value of DKK 2 each and a total of 1,903,982,092 voting rights.

 Nominal Value, DKKNumber of shares
A shares107,487,20053,743,600
B shares829,110,092414,555,046
Total936,597,292468,298,646



Contact information
Investor Relations  
Tobias Bjorklund
Anders Enevoldsen




Media Relations		  
Lina Danstrup



   



 

Attachment



EN
31/01/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Q1 update: Novonesis delivers 4% organic sales growth in line with exp...

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024. In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolution...

May 3, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading statement Q1 2024

Trading statement Q1 2024 Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.” Pro forma sales perfo...

May 3, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Resolutions from the annual shareholders’ meeting 2024

Resolutions from the annual shareholders’ meeting 2024 Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:•  Approval of the audited Annual Report for 2023•  Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.•  Approval of the Remuneration Report fo...

April 30, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Invitation to the annual shareholders’ meeting

Invitation to the annual shareholders’ meeting The annual shareholders’ meeting will be held on Tuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark. The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis’ adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a ...

April 8, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Share-based legacy RSU program granted

Share-based legacy RSU program granted Share-based legacy RSU program granted Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S (“Chr. Hansen”) today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention. The KPIs include personal targets and financial performance indi...

April 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch